Investor Relations

OPKO Launches the 4Kscore Test in Europe more »

Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference more »

OPKO Licensee TESARO Submits New Drug Application for Rolapitant more »

OPKO Announces Second Quarter Operating and Financial Results more »

Investor FAQs